Moxifloxacin Krka (Moxifloxacin)

• Moxifloxacin is a fluoroquinolone antibiotic indicated for several bacterial infections affecting the respiratory tract and skin.
• Community‑acquired bacterial pneumonia: eradicates the causative pathogens and improves clinical symptoms.
• Acute bacterial sinusitis: reduces sinus inflammation and clears infection.
• Acute bacterial exacerbation of chronic bronchitis: shortens the duration of exacerbation and restores lung function.
• Skin and soft‑tissue infections: eliminates susceptible bacteria and promotes wound healing.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By binding to these enzymes, it prevents the supercoiling and separation of DNA strands, leading to bacterial cell death. The dual targeting of both enzymes enhances activity against Gram‑positive, Gram‑negative, and atypical organisms, contributing to its broad‑spectrum antibacterial effect.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea
• Diarrhea
• Headache
• Dizziness
• Rash

Serious or Rare Side Effects

• Tendon rupture or inflammation
• QT interval prolongation leading to arrhythmia
• Severe allergic reactions such as anaphylaxis
• Clostridioides difficile‑associated colitis

Before prescribing moxifloxacin, clinicians should consider several precautionary measures to minimize risk.

• Assess renal and hepatic function: adjust therapy if impairment is present.
• Monitor for tendon pain or swelling: discontinue if signs of tendonitis appear.
• Avoid concomitant use with other QT‑prolonging agents: increased risk of cardiac arrhythmias.
• Use with caution in patients with a history of seizures: may lower seizure threshold.
• Review anticoagulant therapy: warfarin may require INR monitoring.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Moxifloxacin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Antacids or supplements containing magnesium, aluminum, calcium, or iron: reduce absorption of moxifloxacin.
• Drugs that prolong the QT interval (e.g., macrolide antibiotics, antiarrhythmics): increase risk of cardiac arrhythmias.
• Warfarin: may enhance anticoagulant effect and raise INR.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: efficacy may be decreased, consider alternative contraception.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase central nervous system side effects.